Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jason M. Summa
Observed names:
J. Summa,
Jason Mark Summa,
Jason Summa
Observed institution:
Janssen Research & Development (United States)
OpenAlex ID:
A5082348569
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
2012
·
Jeffrey Hrkach
, Daniel Von Hoff
, et al.
·
Science Translational Medicine
·
1,148
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2016
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
·
Clinical Cancer Research
·
289
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
2018
·
Karen A. Autio
, Robert Dreicer
, et al.
·
JAMA Oncology
·
278
PDF
Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
2019
·
M.R. Smith
, S.K. Sandhu
, et al.
·
Annals of Oncology
·
93
Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
2019
·
Matthew Raymond Smith
, Shahneen Kaur Sandhu
, et al.
·
Journal of Clinical Oncology
·
63
A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
2016
·
Karen A. Autio
, Jorge A. Garcia
, et al.
·
Journal of Clinical Oncology
·
33
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
2020
·
Matthew Raymond Smith
, Karim Fizazi
, et al.
·
Journal of Clinical Oncology
·
19
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer
2014
·
R. Natale
, M. Socinski
, et al.
·
European Journal of Cancer
·
17
Abstract LB-203: A phase I study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors.
2013
·
Daniel D. Von Hoff
, Monica Mita
, et al.
·
Cancer Research
·
10
Abstract CT210: A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule
2014
·
Monica Mita
, Howard Burris
, et al.
·
Cancer Research
·
8
Abstract LB-452: A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer
2012
·
Jason Summa
, Patricia M. LoRusso
, et al.
·
Cancer Research
·
4
Abstract 5514: Pharmacokinetics of BIND-014 (docetaxel nanoparticles for injectable suspension) in preclinical species and patients with advanced solid tumors
2015
·
Jason Summa
, Daniel Von Hoff
, et al.
·
Cancer Research
·
2
Abstract 911: Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel
2014
·
Susan Low
, Daniel Von Hoff
, et al.
·
Cancer Research
·
2
Supplemental Section - Clean from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
PDF
Supplemental Section - Clean from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
Supplementary Figure 2 from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
Data from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
Data from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
Supplementary Figure 2 from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
2023
·
Daniel D. Von Hoff
, Monica M. Mita
, et al.
Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study
2015
·
Jason M. Summa
, Daniel D. Von Hoff
, et al.
·
Molecular Cancer Therapeutics
Abstract A161: Cardiovascular safety profile of BIND-014 (docetaxel nanoparticles for injectable suspension) evaluated in phase 1 and 2 studies
2015
·
Jason Summa
, Jean Kung
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
21
Citation count:
1,966
H-index:
9
I10-index:
9
Year
Topic
Type
